Myrbetriq approved for overactive bladder

June 28, 2012

(HealthDay) -- Myrbetriq (mirabegron) has been approved to treat adults with overactive bladder, a condition affecting some 33 million Americans, the U.S. Food and Drug Administration said Thursday in a news release.

The drug is designed to relax the as the bladder fills, minimizing the potential symptoms of needing to urinate too often, needing to urinate immediately or the involuntary leakage of urine, the agency said.

The drug's safety and effectiveness were evaluated in clinical studies involving 4,116 people with overactive bladder. The most common side effects were a rise in blood pressure, cold-like symptoms, urinary tract infection, constipation, fatigue, increased heart rate and abdominal pain.

Myrbetriq is marketed by Astellas Pharma US, based in Northbrook, Ill.

More information: The U.S. National Library of Medicine has more about overactive bladder.


Related Stories

US approves Botox for bladder control

August 24, 2011

The face-freezing pharmaceutical injection Botox gained another medical use on Wednesday when the US government approved it for use in some patients with overactive bladder.

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.